|
Q2 FY2027
As of Sep 30, 2026
|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
|
|---|---|---|---|---|---|---|
| Cash | ||||||
| Advance – related party | ||||||
| Prepaid expenses | ||||||
| Total Current Assets | ||||||
| Deferred offering costs | ||||||
| Investments held in Trust Account | ||||||
| Total Assets | ||||||
| Accrued expenses | ||||||
| Promissory note – related party | ||||||
| Due to related party | ||||||
| Total Current Liabilities | ||||||
| Deferred underwriting fee payable | ||||||
| Total Liabilities | ||||||
| Ordinary shares subject to possible redemption, 8,280,000 shares and 0 shares at redemption value of $10.25 and $0 per share as of March 31, 2026 and March 31, 2025, respectively | ||||||
| Ordinary shares subject to possible redemption, $0.0001 par value, 8,280,000 shares at redemption value of $10.43 per share and $10.25 per share as of September 30, 2026 and March 31, 2026, respectively | ||||||
| Ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 3,126,650 shares issued and outstanding as of September 30, 2026 and March 31, 2026 (excluding 8,280,000 shares subject to possible redemption) | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total Shareholders’ (Deficit) Equity | ||||||
| Total Shareholders’ Deficit | ||||||
| Total Liabilities, Shares Subject to Possible Redemption and Shareholders’ Deficit |
Loading...